Review: antibiotic prophylaxis may not prevent recurrent symptomatic urinary tract infection in children QUESTION In children [patients] with and without vesicoureteric refl ux (VUR), do long-term antibiotics [intervention] prevent urinary tract infection (UTI) [outcome]?
MAIN RESULTS
The 11 trials included a total of 2046 children. All but one trial included children with VUR. The quality of trials varied (only three described the allocation concealment process, only two were double-blinded, only four had intention to treat analysis). The treatment regimen was usually co-trimoxazole or nitrofurantoin. The duration of prophylaxis and method of urine collection also varied. Losses to follow-up were low (0-21.9%).
Recurrent single symptomatic UTI was not reduced by prophylaxis (RR 0.83, 95% CI 0.66 to 1.05). Prophylactic effi cacy was not affected by a priori subgroup analysis considering children with or without VUR, site of UTI or duration of treatment. It was, however, affected when trials were divided by study quality: in trials with adequate allocation concealment, recurrent UTI was reduced by prophylaxis (RR 0.68, 95% CI 0.48 to 0.95). Antibiotic prophylaxis reduced the risk of a repeat positive urine culture. There was no signifi cant difference in the rate of new or deteriorated renal scars. The most common adverse events were vomiting or gastrointestinal intolerance (7.3% reported in one study). Four studies reported the development of resistant bacteria: most UTIs of patients in the intervention groups were caused by resistant microorganisms. Publication bias was not evident using a funnel plot.
CONCLUSIONS
In children with or without VUR, antibiotic prophylaxis may not prevent recurrent symptomatic UTI (table 1) . COMMENTARY G iving antibiotic prophylaxis to children at risk of recurrent urinary tract infections (UTIs) seems like a very logical thing to do. It has been recommended for many years, especially in children with vesicoureteric refl ux (VUR). The problem is, it doesn't seem to help prevent the more relevant outcomes: symptomatic UTIs and renal scarring.
ABSTRACTED FROM
The results of this well-conducted systematic review indicate that there may be a very small benefi t from prophylaxis. It clearly shows that antibiotics prevent a repeat positive urine culture, but this is a surrogate outcome. What really matters for the patient are symptomatic -meaning febrile -infections and renal scarring. Febrile infections may lead to scarring, and scarring may lead to longer term morbidity such as hypertension and renal failure. In these two outcomes, antibiotic prophylaxis fails to show a signifi cant benefi t, even in children with VUR.
The oldest studies included in this review had a few methodological limitations: they were not blinded, there was inadequate allocation concealment and they were conducted in small populations. This may have overestimated previous results. Also, the method for urine recollection was usually by sterile bag, which simply is not recommended for use. 1 But the more recent trials have been better designed, and still we have a lot of doubt about the true effect of antibiotic prophylaxis in children at risk of recurrent UTIs.
Let's give antibiotics the benefi t of the doubt for a second. The pooled RR for recurrent UTIs is 0.83, although the 95% CI crosses 1 (0.66 to 1.05). Could it be that if we add more trials and more patients the RR will reach statistical signifi cance? Maybe. And we'll see if this is true in future trials. But if this happens, it probably also means that we need a lot of patients to prevent one UTI.
Then, there's renal scarring, which really is the main reason to prevent UTIs in the fi rst place. The RR for this outcome is almost 1 (0.95, with 95% CI 0.51 to 1.78). Studies have failed consistently to show any benefi t to prevent new or deteriorating renal scars. And fi nally, there's the matter of side effects. Although the more frequent adverse effects are mild (nausea, gastrointestinal intolerance), the most important one is bacterial resistance. Most UTIs in the intervention groups of these trials were caused by resistant bacteria.
As good and as logical as it sounds, antibiotic prophylaxis has come up short. And it's not the fi rst time this apparently logical approach has failed -see infectious endocarditis. 2 Right now, there may be more reasons not to give prophylaxis than to give. It seems prudent to use a watchful waiting approach in children at risk of UTI, instead of automatically prescribing antibiotics for months. Future research 3 will help us decide if there are some high risk groups (such as children with VUR grade III-V) in which this intervention might be worth it. 
